Avzivi® (BAT1706) is Bio-Thera Solution’second FDA approved product in the United States Avzivi® is the second biosesimilar researched,developed, and manufactured by a Chinese pharmaceutical company to receive FDAapproval in the United States Guangzhou, China – December 7, 2023 – Bio-TheraSolu...
DetailsGUANGZHOU, China - Bio-Thera Solutions (688177.S H ), a commercial-stage biopharmaceutical company developinginnovative therapies and biosesimilars, announced that its partner, Biogen Inc.(Nasdaq: BIIB) officially launched TOFIDENCE (tocilizumab-bavi) intravenousformulation, a biosesimilar monoclonal an...
Guangzhou, China -- Bio-Thera Solutions(688177:SH), a commercial-stage biopharmaceutical company developing a pipelineof innovative therapies and biosesimilars, today announced receiving INDclearance from the US FDA for a phase II Study for BAT8006, an innovative AntibodyDrug Conjugate (ADC) targeting...
GUANGZHOU, China and San José, Costa Rica- Bio-Thera Solutions, a commercial-stagebiopharmaceutical company developing innovative therapies and biosesimilars, andSteinCares, one of Latin America’s leading specialty healthcare companies,announced today a new licensing agreement for two biosesimilars u...
